Press releases

Press releases

16 April 2015  - Paris (France)

Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer

08 April 2015  - Paris (France)

Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors

01 April 2015  - Paris (France)

Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement

01 April 2015  - Paris (France)

Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence

31 March 2015  - Paris (France)

The Ipsen Group publishes its 2014 Registration document

04 March 2015

Precisions concerning the resupply of Increlex® in the U.S.

03 March 2015  - Paris (France)

Ipsen’s 2014 results and 2015 financial objectives

02 March 2015  - Paris (France)

Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

02 March 2015  - Paris (France)

Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer

24 February 2015  - Paris (France)

Ipsen enters into option agreement to acquire Canbex Therapeutics